|
|
|
|
|
Melphalan
drug data and news
Melphalan drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Melphalan | ||
| Brand Names/Synonyms | 3025 C. B.; ALKERAN; AT-290; Alkeran; CB 3025; L-PAM; L-Phenylalanine Mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Levofalan; Melfalan; Melphalan; Mephalan; NSC 8806; NSC-8806; Phenylalanine Mustard; Phenylalanine Nitrogen Mustard; Sarcolysine; Sarkolysin | ||
| Indication | Used to treat cancer of the ovaries and a certain type of cancer in the bone marrow | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Melphalan is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death. | ||
| Mechanism Of Action | Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. | ||
| Melphalan News (When available) |
Velcade® plus Melphalan Shows Encouraging Activity in Multiple ... Feb 23, 2006 Delcath Systems Announces Initial Patient Treatment In Phase III ... Mar 1, 2006 Delcath Systems Receives Special Protocol Assessment and Agreement ... Feb 22, 2006 Doxil® in the VAD Regimen for Myeloma Confirmed Less Toxic Than ... Feb 28, 2006 Delcath Systems initiates phase III trial in melanoma Mar 2, 2006 Delcath Systems receives FDA OK for cancer trial Feb 22, 2006 Delcath Systems Receives NCI Institutional Review Board Approval Feb 7, 2006 Gentium to Present at Angiogenesis in Cancer and Vascular Disease ... Feb 2, 2006 Treanda™/Prednisone Superior to Melphalan/Prednisone for ... Jan 30, 2006 Treanda TM (Bendamustine) Plus Prednisone Superior to Melphalan ... Jan 27, 2006 Delcath Systems Receives NCI Institutional Review Board Approval Feb 7, 2006 Celgene Corporation Reports Record Operating Performance for 2005 Jan 26, 2006 Gentium to Present at Angiogenesis in Cancer and Vascular Disease ... Feb 2, 2006 Millennium Achieves 2005 Financial Guidance Jan 26, 2006 Delcath Systems Co-Sponsors First International Symposium On ... Jan 24, 2006 Delcath Systems to Present at Brean Murray, Carret & Co. Small Cap ... Jan 26, 2006 Natco Pharma launches blood cancer drug Dec 8, 2005 Delcath Receives Additional US Patent for Cancer Treatment System Dec 8, 2005 Delcath dealt another patent for chemotherapy delivery system Dec 8, 2005 New Data on VELCADE(R) (bortezomib) for Injection to Be Presented ... Dec 6, 2005 Delcath Systems Announces Listing of Warrants Dec 1, 2005 Delcath Receives Canadian Patent for Novel Apparatus and Method ... Nov 21, 2005 Melphalan/Prednisone Favorable in Multiple Myeloma Patients ... Sep 30, 2005 Alkeran®/Prednisone Remains Standard Therapy for Elderly Patients ... Oct 4, 2005 Zevalin® May Substitute for Total Body Irradiation When Combined ... Oct 6, 2005 Committee for Medicinal Products for Human Use Post-authorisation ... Sep 16, 2005 Ethyol® Allows Greater Tolerability of Chemotherapy in Head and ... Sep 29, 2005 *vwd/BUSINESS WIRE: Gentium SpA gibt Beginn der unabhängigen ... Sep 21, 2005 High-Dose Sequential Chemotherapy and Autologous Stem Cell ... Sep 13, 2005 Gentium SpA Announces Initiation of Independent Phase I/II Study ... Sep 21, 2005 High-Dose Sequential Chemotherapy and Autologous Stem Cell ... 08 Sep 2005 Mayo Clinic Research Shows Promise For Myeloma Patients Using A ... Sep 2, 2005 Multiple myeloma, Revlimid and Dexamethasone show promise Sep 3, 2005 Chemotherapy and Autologous Stem Cell Transplant Improve Outcome ... Aug 23, 2005 Efficacy of High-Dose Chemotherapy with Autologous Stem Cell ... Aug 19, 2005 Combination chemotherapy with gemcitabine with isolated lung ... Jul 12, 2005 Correlation Between Serum Levels of Free Light Chain and Phenotype ... Jul 14, 2005 Delcath Reports on 2005 Annual Meeting Jun 15, 2005 Two Studies Show Zevalin® Effective in Elderly Patients with ... Jun 30, 2005 Two New Studies in the British Journal of Haematology Show ... Jun 8, 2005 Combined Use of ^Sup 99m^Tc-Sestamibi and ^Sup 99m^Tc-V-DMSA in ... Jun 15, 2005 | ||
| Dosage Forms | tablets, injection | ||
| Drug_Category | Antineoplastic Agents; ATC:L01AA03 | ||
| Absorption | incomplete, variable, 25-89% post oral dose | ||
| Interactions | DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis. Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease | ||
| Toxicity | vomiting, ulceration of the mouth, diarrhea, and hemorrhage of the gastrointestinal tract. The principal toxic effect is bone marrow suppression, LD50=11.2mg/kg (orally in rat) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]-propanoicacid | ||
| Chemical Formula | C13H18Cl2N2O2 | ||
| Molecular Weight | 305.2 g/mol | ||
| Smiles String | C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl | ||
| Melting Point | 177°C | ||
| Water Solubility | <0.1 g/100 mL at 22 C | ||
| State | Solid | ||
| LogP/Hphobicity | -0.432 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 1.5 (+/-0.83) hours | ||
| Protein Binding [%] | 60% to 90% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Melphalan.html http://www.rxlist.com/cgi/generic2/melph.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00118 | ||
| CAS Registry Number | 148-82-3 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:369593 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 4715 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |